Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials

Abstract

AbstractAimsTo evaluate gastrointestinal adverse events (AEs) and the impact of nausea, vomiting or diarrhoea (N/V/D) and any gastrointestinal (GI) AEs overall on weight change with tirzepatide across the SURPASS‐1 to ‐5 clinical trials.Materials and MethodsParticipants with type 2 diabetes were randomized to receive once‐weekly tirzepatide (5, 10 or 15 mg) or comparator (placebo, semaglutide 1 mg once weekly, or titrated daily basal insulins) as monotherapy or added on to background antihyperglycaemic medication(s). This post hoc analysis subdivided participants within each trial into subgroups that self‐reported (yes/no) any N/V/D or GI AEs. Change from baseline in body weight at the primary timepoint was assessed within each trial and subgroup. Mediation analyses were conducted to evaluate the contribution of direct and indirect (mediated by N/V/D or GI AEs) effects of tirzepatide on weight change versus comparators.ResultsAcross the SURPASS‐1 to ‐5 trials (N = 6263), nausea (12%‐24%), diarrhoea (12%‐22%), and vomiting (2%‐13%) were the most common GI AEs reported with tirzepatide; these were transient and of mild‐to‐moderate severity. Mean weight reduction at the primary timepoint with tirzepatide was consistent between participants who reported N/V/D (−6.2 to −14.9 kg) and those who did not report N/V/D (−6.2 to −13.3 kg). Mean weight reduction was significantly (P < 0.01) greater with tirzepatide compared with placebo, semaglutide 1 mg, and basal insulins within the N/V/D and GI AEs subgroups. Mediation analyses suggested minimal contribution (<6%) of N/V/D and GI AEs to the overall difference in weight change between tirzepatide and comparators.ConclusionsSuperior weight reduction with tirzepatide versus comparators appears to be independent of reported N/V/D or GI AEs.